Unveiling the Human Proteome: UK Biobank Pharma Proteomics Project

Accelerating Biomarker Discovery

The UK Biobank Pharma Proteomics Project (UKB-PPP), a groundbreaking endeavor, aims to create an unprecedented map of disease-associated protein levels in the human body. Utilizing Thermo Fisher Scientific's Olink Explore Platform, this ambitious project will analyze over 5,400 proteins from 600,000 samples, paving the way for the identification of novel protein biomarkers that hold the key to predicting, diagnosing, and effectively treating a wide range of diseases.

Unveiling the Role of Proteins in Health and Disease

"Studies on the human proteome have revolutionized our understanding of disease and life sciences research," remarked Marc N. Casper, CEO of Thermo Fisher. "This project, powered by our Olink Explore Platform, will deepen our knowledge and unlock new pathways for improving human health."

Empowering Precision Medicine through Protein Signatures

The Olink Explore Platform enables researchers to comprehensively study the thousands of proteins in the human body, revealing their role in various diseases. "Protein signatures hold the potential to advance precision medicine," said Professor Naomi Allen, UK Biobank's chief scientist. "They can help diagnose diseases, identify individuals at risk of developing dementia or cancer, and pinpoint drug targets."

Uniting Expertise for Groundbreaking Collaborations

UKB-PPP is a collaboration between UK Biobank and 14 leading biopharmaceutical companies. "Success depends on reliable and effective partners," said Chris Whelan, principal investigator of UKB-PPP. "We are thrilled to have Olink platform as the driving force behind this transformative study."

Building on Pilot Project Discoveries

This project builds on the successful pilot project, which leveraged the Olink Explore platform to analyze over 54,000 samples. Published findings from this pilot study in Nature showcased how protein risk factors can identify certain cancers up to seven years before traditional diagnosis.

Timing and Results Dissemination

UKB-PPP is expected to commence in Q1 2025, with proteomic data becoming available to UK Biobank-approved researchers in stages starting in 2026. The full dataset will be released in 2027.

Thermo Fisher Scientific's Commitment to Innovation

"Acquired by Thermo Fisher in 2024," said Sandy Pound, media contact for Thermo Fisher Scientific, "the Olink proteomics platform empowers researchers with unparalleled specificity, speed, and flexibility."